Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00321217|
Recruitment Status : Unknown
Verified November 2011 by Radboud University.
Recruitment status was: Recruiting
First Posted : May 3, 2006
Last Update Posted : August 16, 2012
|Condition or disease|
Rheumatoid Arthritis (RA) is a severe inflammatory disease and genetic factors are known to play an important role in its pathogenesis. Genetic factors are also involved in determining the prognosis of RA. Identifying the genetic factors that predispose to mild or aggressive RA is not easy and up to now only a few of these factors -like certain HLA-DR species- are known.
The Rheumatology department of the Radboud University Nijmegen Medical Centre (RUNMC) has collected a unique inception cohort of over 500 patients with RA, that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity, joint damage and other characteristics of disease progression.
In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activity/progression.
|Study Type :||Observational|
|Estimated Enrollment :||700 participants|
|Official Title:||Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis|
|Study Start Date :||May 2004|
|Estimated Primary Completion Date :||November 2013|
|Estimated Study Completion Date :||April 2014|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00321217
|Contact: M. J. Coenen, PhDfirstname.lastname@example.org|
|Arnhem, Netherlands, 6800 TA|
|Contact: C. MA de Gendt, MD 0031-26-3787788 DdeGendt@alysis.nl|
|Radboud University Nijmegen Medical Centre||Recruiting|
|Nijmegen, Netherlands, 6500 HB|
|Contact: P. Barrera, PhD 0031-24-3617649 email@example.com|
|Nijmegen, Netherlands, 6522 JV|
|Contact: D. JR de Rooij, PhD 0031-24-3659280 D.firstname.lastname@example.org|
|Principal Investigator:||M. J. Coenen, PhD||Radboud University|